Open AccessChemo‐immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé Yet?
Author(s) -
Danilov Alexey V.,
Pagel John M.,
Brown Jennifer R.,
Hill Brian T.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000275
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , bendamustine , rituximab , oncology , fludarabine , chlorambucil , immunotherapy , bruton's tyrosine kinase , chemoimmunotherapy , idelalisib , alemtuzumab , cyclophosphamide , immunology , leukemia , tyrosine kinase , chemotherapy , cancer , lymphoma , transplantation , receptor
Chemo-immunotherapy regimens such as fludarabine, cyclorandomized study of ibrutinib, a Bruton tyrosine kinase phosphamide and rituximab (FCR), and bendamustine-rituximab (BR) have long been mainstays of therapy in chronic lymphocytic leukemia (CLL). However, in the past decade, recognition of the role of the microenvironment in the pathogenesis of CLL led to the development of targeted inhibitors of the B-cell receptor signaling-associated kinases. This resulted in a paradigm shift in treatment of CLL patients and significantly improved the natural history of the disease. The seminal paper published by Woyach et al from the Alliance for Clinical Trials in Oncology Cooperative Group further highlights the importance of targeted therapy in CLL. This